Centro de Investigación en Ciencias Moleculares

Efforts to develop a vaccine against HIV in Puerto Rico

Manuel Delgado-Vélez's picture

Even before its discovery in the mid-80s, the human immunodeficiency virus (HIV) was already responsible for one of the most devastating pandemics in the history of humankind. Since then there have been significant advances, ranging from the approval by the FDA ("Food and Drug Administration") of the first antiretroviral drug, zidovudine (AZT) in 19871; to the launch in 2015 by the World Health Organization (WHO) of the recommendation that all HIV-infected individuals should receive antiretroviral therapy immediately after being diagnosed.2  

First phase in HIV vaccine project is completed

This article is reproduced by CienciaPR with permission from the original source.

CienciaPR Contribution: 



Keila López Alicea

The University of Puerto Rico (UPR) is actively engaged in the race to develop a vaccine against HIV. In just 18 month, researchers from the Molecular Sciences Research Center at UPR have succesfully completed the first phase of a project to develop an HIV vaccine and are waiting for NIH aproval to begin the second phase. 

For the full article, please refer to the spanish version of this site. 



Subscribe to Centro de Investigación en Ciencias Moleculares